Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Summary

This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.

Timeline

Start

2015-01-19

Primary completion

2015-06-19

Completion

2015-06-19

Publications

• Palmer M, Jennings L, Silberg DG, Bliss C, Martin P. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10. doi: 10.1186/s40360-018-0200-y.

Drugs

Indications